PerkinElmer (NYSE:PKI) is scheduled to announce its earnings results after the market closes on Wednesday, October 31st. Analysts expect the company to announce earnings of $0.92 per share for the quarter. PerkinElmer has set its FY18 guidance at approx $3.65 EPS.
PerkinElmer (NYSE:PKI) last posted its earnings results on Wednesday, August 1st. The medical research company reported $0.91 EPS for the quarter, beating the consensus estimate of $0.86 by $0.05. PerkinElmer had a return on equity of 14.25% and a net margin of 5.51%. The company had revenue of $703.55 million for the quarter, compared to the consensus estimate of $694.70 million. During the same quarter in the prior year, the business earned $0.67 earnings per share. The firm’s revenue for the quarter was up 28.6% on a year-over-year basis. On average, analysts expect PerkinElmer to post $4 EPS for the current fiscal year and $4 EPS for the next fiscal year.
PerkinElmer stock opened at $83.99 on Monday. PerkinElmer has a 12 month low of $69.21 and a 12 month high of $98.33. The company has a debt-to-equity ratio of 0.79, a quick ratio of 1.17 and a current ratio of 1.69. The company has a market capitalization of $9.30 billion, a PE ratio of 28.96, a PEG ratio of 1.82 and a beta of 1.00.
In related news, insider Deborah A. Butters sold 3,266 shares of the stock in a transaction that occurred on Monday, October 1st. The stock was sold at an average price of $97.70, for a total transaction of $319,088.20. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, insider Daniel R. Tereau sold 3,308 shares of the stock in a transaction that occurred on Monday, September 24th. The stock was sold at an average price of $96.58, for a total value of $319,486.64. Following the sale, the insider now directly owns 10,092 shares in the company, valued at approximately $974,685.36. The disclosure for this sale can be found here. Insiders have sold 70,443 shares of company stock worth $6,145,255 in the last three months. 2.10% of the stock is currently owned by company insiders.
A number of brokerages recently issued reports on PKI. Robert W. Baird reissued a “buy” rating and set a $89.00 price target on shares of PerkinElmer in a research report on Thursday, August 2nd. ValuEngine raised PerkinElmer from a “hold” rating to a “buy” rating in a research report on Thursday, July 26th. Cleveland Research raised PerkinElmer from a “neutral” rating to a “buy” rating in a research report on Thursday, August 30th. Barclays raised PerkinElmer from an “underweight” rating to an “equal weight” rating and increased their price target for the stock from $79.00 to $90.00 in a research report on Wednesday, September 5th. Finally, Deutsche Bank increased their price target on PerkinElmer from $88.00 to $93.00 and gave the stock a “hold” rating in a research report on Monday, September 10th. Eight research analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. The company currently has a consensus rating of “Hold” and a consensus target price of $87.84.
PerkinElmer Company Profile
PerkinElmer, Inc provides products, services, and solutions to the diagnostics, research, environmental, industrial, food, and laboratory services markets worldwide. The company operates in two segments, Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytical Solutions segment offers analytical technologies, solutions, and services for the environmental market that enable its customers to understand the characterization and health of various aspects, including air, water, and soil.
Recommended Story: What is a put option?
Receive News & Ratings for PerkinElmer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PerkinElmer and related companies with MarketBeat.com's FREE daily email newsletter.